Merck presented pivotal Phase 3 results showing its oral PCSK9 inhibitor produced LDL‑C reductions comparable to injectable PCSK9 antibodies in large trials reported at the American Heart Association. The CORALreef program data reported near‑60% LDL‑C drops at 24 weeks in broad and familial hypercholesterolemia cohorts, positioning the pill as a potential primary‑care alternative to injections. Analysts noted the oral route and room‑temperature storage could materially expand uptake if regulators concur on the totality of safety and efficacy data.